Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells

Published:2019-03-13 Issue:6 Volume:20 Page:855-865
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Ma Ling¹²,Wei Jia²,Su Gloria H.³,Lin Jiayuh²

Affiliation:

1. Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

2. Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD, USA

3. Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA

Funder

University of Maryland school of medicine and comprehensive cancer center start-up fund

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2019.1579956

Reference41 articles.

1. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

2. Pancreatic Cancer

3. Cancer statistics, 2017

4. Overcoming drug resistance in pancreatic cancer

5. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DualSyn: A dual-level feature interaction method to predict synergistic drug combinations;Expert Systems with Applications;2024-12

2. Investigation of the relationship between COVID-19 and pancreatic cancer using bioinformatics and systems biology approaches;Medicine;2024-08-02

3. Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer;International Journal of Molecular Sciences;2024-07-06

4. SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction;Briefings in Bioinformatics;2024-01-22

5. Different combination therapies pertaining to pancreatic cancer;Recent Advances in Nanocarriers for Pancreatic Cancer Therapy;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3